The Medical Letter on Drugs and Therapeutics
A Percutaneous Device (MitraClip) for Mitral Regurgitation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the use of a transcatheter mitral valve device (MitraClip – Abbott) for percutaneous treatment of significant symptomatic degenerative mitral regurgitation (grade 3-4+) in patients who are at prohibitive risk for mitral valve surgery. It is the first percutaneous nonsurgical treatment approved for this indication.

TREATMENT OF MITRAL REGURGITATION — Surgery to repair or replace the mitral valve is the first-line treatment for patients with moderately-severe (grade 3+) to severe (grade 4+) mitral regurgitation, but it generally involves open heart surgery and cardiopulmonary bypass and can cause complications such as bleeding, infection, arrhythmia, and stroke.

THE NEW DEVICE — The MitraClip is implanted percutaneously using fluoroscopy and a transesophageal echocardiogram without stopping the heart or cardiopulmonary bypass. The device grasps the mitral ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Percutaneous Device (MitraClip) for Mitral Regurgitation
Article code: 1432c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian